MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline
The psychedelics-focused medicines company MindMed (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ), announced its second-quarter financial results Friday with a net and comprehensive loss of $36 million, which compares to a loss of $14 million in the previous qua
